1|Page
NR565 WEEK6 RESPIRATORY
PROTOCOL ASSIGNMENT WITH
COMPLETE QUESTIONS AND ANSWERS
— ADVANCED PRACTICE BANK
INTRODUCTION
NR565 Week 6 focuses on pharmacotherapy for respiratory conditions, with particular emphasis
on asthma management and respiratory medication safety. The respiratory protocol assignment
requires students to apply pharmacologic principles and current clinical practice guidance to
patient-specific asthma presentations, including symptom assessment, treatment selection,
monitoring, treatment failure, and referral considerations. Publicly available NR565 course
materials identify asthma pharmacotherapy, albuterol, salmeterol, montelukast, inhaled
corticosteroids, systemic corticosteroids, LABAs, anticholinergics, and theophylline among
important Week 6 concepts.
This advanced practice bank is designed for graduate nursing students preparing for Week 6
assessments and related respiratory pharmacology work. The questions emphasize clinical
application rather than simple memorization. Scenarios require interpretation of symptom
frequency, medication mechanisms, adverse effects, drug interactions, inhaler technique,
treatment response, special populations, and escalation of therapy. Current asthma guidance
emphasizes ICS-containing treatment and individualized assessment of symptom control, risk
factors, adherence, inhaler technique, lung function, and patient preferences before treatment
decisions are made.
CONTENT AREA OVERVIEW
Content Area Questions Key Topics Weight
1. Asthma Assessment & Symptoms, control, severity, triggers,
1–12 12%
Classification lung function, risk factors
2. Asthma Controller & Reliever ICS, ICS-formoterol, SABA, LABA,
13–28 16%
Pharmacotherapy MART, step therapy
3. Corticosteroids & Adverse ICS, systemic steroids, monitoring,
29–38 10%
Effects prevention of complications
4. Bronchodilators & Albuterol, LABAs, LAMAs, ipratropium,
39–50 12%
Anticholinergics mechanisms, safety
5. Leukotriene Modifiers & Other Montelukast, theophylline, biologics,
51–60 10%
Asthma Drugs phenotype-directed therapy
,2|Page
Content Area Questions Key Topics Weight
GOLD principles, LABA/LAMA, ICS
6. COPD Pharmacotherapy 61–72 12%
indications, exacerbations
7. Respiratory Infections & TB TB regimens, rifampin, isoniazid,
73–82 10%
Pharmacotherapy interactions, monitoring
8. Antihistamines & H1 blockers, adverse effects,
83–90 8%
Decongestants sympathomimetics, precautions
9. Integrated Clinical Decision- Special populations, treatment failure,
91–100 10%
Making monitoring, referral
QUESTIONS 1–100
CONTENT AREA 1 — ASTHMA ASSESSMENT &
CLASSIFICATION
Q1:
A 24-year-old patient reports wheezing and chest tightness approximately twice weekly, with
symptoms triggered by exercise and seasonal allergens. Lung function is normal between
episodes. Which initial pharmacologic approach is most consistent with current asthma guidance
for an adult with infrequent symptoms?
A) Daily oral prednisone with albuterol as needed
B) As-needed low-dose ICS-formoterol
C) SABA-only treatment without an ICS-containing medication
D) Daily high-dose ICS-LABA regardless of symptom burden
*Rationale: The correct answer is B because current GINA guidance recommends an ICS-
containing strategy for adults with asthma and identifies as-needed low-dose ICS-formoterol as a
preferred initial approach for infrequent symptoms. A exposes the patient to unnecessary
systemic corticosteroid toxicity. C leaves the patient without anti-inflammatory treatment. D
provides substantially more controller therapy than the described presentation generally requires.
GINA specifically advises against SABA-only treatment because it does not adequately address
airway inflammation and exacerbation risk. *
Q2:
A patient reports asthma symptoms on most days and awakening from asthma approximately
once weekly. Which finding would most strongly support the need for an ICS-formoterol
maintenance-and-reliever strategy?
A) Normal lung function and no nighttime symptoms
B) Symptoms occurring only after vigorous exercise once monthly
,3|Page
C) Symptoms on most days with recurrent nighttime awakening
D) A single episode of wheezing three years ago
Rationale: The correct answer is C because frequent daytime symptoms and nighttime
awakening indicate a greater level of asthma burden and warrant controller therapy rather than
occasional symptom treatment alone. A and D describe substantially lower symptom burden. B
suggests intermittent symptoms and does not justify the same intensity of maintenance therapy.
Q3:
A patient with asthma reports using a rescue inhaler repeatedly every day. Which assessment
should occur before simply increasing medication?
A) Determine the patient's blood type
B) Assess adherence, inhaler technique, triggers, comorbidities, and current symptom
control
C) Immediately prescribe chronic oral corticosteroids
D) Discontinue all controller therapy
Rationale: The correct answer is B because uncontrolled symptoms should prompt evaluation of
modifiable causes before escalation. Incorrect inhaler technique, poor adherence, ongoing
exposures, and comorbidities can all produce apparent treatment failure. Chronic systemic
corticosteroids are not an appropriate automatic response, and discontinuing controller therapy
may worsen disease control.
Q4:
A patient reports cough and wheezing that worsen during pollen season but improve
substantially during winter. Which clinical feature most strongly supports asthma?
A) Fixed symptoms without variation
B) Variable respiratory symptoms and airflow limitation over time
C) Progressive irreversible airflow limitation only
D) Persistent productive cough with no variability
Rationale: The correct answer is B. Asthma is characterized by variable respiratory symptoms
and variable expiratory airflow limitation. A fixed pattern is less characteristic. Progressive
persistent limitation may suggest COPD or another chronic lung disease.
Q5:
A patient with asthma has an Asthma Control Test score indicating poor control. Which
additional assessment is most important before modifying long-term therapy?
A) Hair color
B) Blood type
, 4|Page
C) Medication adherence and inhaler technique
D) Serum sodium alone
Rationale: The correct answer is C because poor adherence or incorrect inhaler technique can
mimic pharmacologic treatment failure. Correcting these factors may improve control without
unnecessarily escalating therapy.
Q6:
A patient has asthma symptoms primarily after exercise. Which statement best describes the
pathophysiological trigger?
A) Exercise permanently destroys alveolar walls
B) Exercise can provoke transient bronchoconstriction in susceptible patients
C) Exercise universally causes pulmonary fibrosis
D) Exercise directly causes bacterial pneumonia
Rationale: The correct answer is B. Exercise can trigger airway narrowing in susceptible
individuals through mechanisms involving airway cooling, drying, and mediator release. It does
not permanently destroy alveolar tissue or directly cause infection.
Q7:
A patient with asthma has frequent exacerbations despite reporting relatively few daily
symptoms. Which conclusion is most appropriate?
A) The patient has no meaningful asthma risk
B) Exacerbation risk should be assessed independently from current symptom frequency
C) Controller therapy should automatically be stopped
D) SABA use is irrelevant to future risk
Rationale: The correct answer is B. Asthma management considers both current symptom
control and future risk of exacerbations. A patient can have relatively few daily symptoms yet
remain at significant risk.
Q8:
A patient with asthma has poor control despite apparently appropriate prescribing. The patient
demonstrates incorrect inhaler technique during observation. What is the most appropriate
immediate intervention?
A) Add three additional controllers
B) Correct inhaler technique and reassess response before escalating therapy
C) Stop all inhaled medications
D) Begin lifelong oral corticosteroids
NR565 WEEK6 RESPIRATORY
PROTOCOL ASSIGNMENT WITH
COMPLETE QUESTIONS AND ANSWERS
— ADVANCED PRACTICE BANK
INTRODUCTION
NR565 Week 6 focuses on pharmacotherapy for respiratory conditions, with particular emphasis
on asthma management and respiratory medication safety. The respiratory protocol assignment
requires students to apply pharmacologic principles and current clinical practice guidance to
patient-specific asthma presentations, including symptom assessment, treatment selection,
monitoring, treatment failure, and referral considerations. Publicly available NR565 course
materials identify asthma pharmacotherapy, albuterol, salmeterol, montelukast, inhaled
corticosteroids, systemic corticosteroids, LABAs, anticholinergics, and theophylline among
important Week 6 concepts.
This advanced practice bank is designed for graduate nursing students preparing for Week 6
assessments and related respiratory pharmacology work. The questions emphasize clinical
application rather than simple memorization. Scenarios require interpretation of symptom
frequency, medication mechanisms, adverse effects, drug interactions, inhaler technique,
treatment response, special populations, and escalation of therapy. Current asthma guidance
emphasizes ICS-containing treatment and individualized assessment of symptom control, risk
factors, adherence, inhaler technique, lung function, and patient preferences before treatment
decisions are made.
CONTENT AREA OVERVIEW
Content Area Questions Key Topics Weight
1. Asthma Assessment & Symptoms, control, severity, triggers,
1–12 12%
Classification lung function, risk factors
2. Asthma Controller & Reliever ICS, ICS-formoterol, SABA, LABA,
13–28 16%
Pharmacotherapy MART, step therapy
3. Corticosteroids & Adverse ICS, systemic steroids, monitoring,
29–38 10%
Effects prevention of complications
4. Bronchodilators & Albuterol, LABAs, LAMAs, ipratropium,
39–50 12%
Anticholinergics mechanisms, safety
5. Leukotriene Modifiers & Other Montelukast, theophylline, biologics,
51–60 10%
Asthma Drugs phenotype-directed therapy
,2|Page
Content Area Questions Key Topics Weight
GOLD principles, LABA/LAMA, ICS
6. COPD Pharmacotherapy 61–72 12%
indications, exacerbations
7. Respiratory Infections & TB TB regimens, rifampin, isoniazid,
73–82 10%
Pharmacotherapy interactions, monitoring
8. Antihistamines & H1 blockers, adverse effects,
83–90 8%
Decongestants sympathomimetics, precautions
9. Integrated Clinical Decision- Special populations, treatment failure,
91–100 10%
Making monitoring, referral
QUESTIONS 1–100
CONTENT AREA 1 — ASTHMA ASSESSMENT &
CLASSIFICATION
Q1:
A 24-year-old patient reports wheezing and chest tightness approximately twice weekly, with
symptoms triggered by exercise and seasonal allergens. Lung function is normal between
episodes. Which initial pharmacologic approach is most consistent with current asthma guidance
for an adult with infrequent symptoms?
A) Daily oral prednisone with albuterol as needed
B) As-needed low-dose ICS-formoterol
C) SABA-only treatment without an ICS-containing medication
D) Daily high-dose ICS-LABA regardless of symptom burden
*Rationale: The correct answer is B because current GINA guidance recommends an ICS-
containing strategy for adults with asthma and identifies as-needed low-dose ICS-formoterol as a
preferred initial approach for infrequent symptoms. A exposes the patient to unnecessary
systemic corticosteroid toxicity. C leaves the patient without anti-inflammatory treatment. D
provides substantially more controller therapy than the described presentation generally requires.
GINA specifically advises against SABA-only treatment because it does not adequately address
airway inflammation and exacerbation risk. *
Q2:
A patient reports asthma symptoms on most days and awakening from asthma approximately
once weekly. Which finding would most strongly support the need for an ICS-formoterol
maintenance-and-reliever strategy?
A) Normal lung function and no nighttime symptoms
B) Symptoms occurring only after vigorous exercise once monthly
,3|Page
C) Symptoms on most days with recurrent nighttime awakening
D) A single episode of wheezing three years ago
Rationale: The correct answer is C because frequent daytime symptoms and nighttime
awakening indicate a greater level of asthma burden and warrant controller therapy rather than
occasional symptom treatment alone. A and D describe substantially lower symptom burden. B
suggests intermittent symptoms and does not justify the same intensity of maintenance therapy.
Q3:
A patient with asthma reports using a rescue inhaler repeatedly every day. Which assessment
should occur before simply increasing medication?
A) Determine the patient's blood type
B) Assess adherence, inhaler technique, triggers, comorbidities, and current symptom
control
C) Immediately prescribe chronic oral corticosteroids
D) Discontinue all controller therapy
Rationale: The correct answer is B because uncontrolled symptoms should prompt evaluation of
modifiable causes before escalation. Incorrect inhaler technique, poor adherence, ongoing
exposures, and comorbidities can all produce apparent treatment failure. Chronic systemic
corticosteroids are not an appropriate automatic response, and discontinuing controller therapy
may worsen disease control.
Q4:
A patient reports cough and wheezing that worsen during pollen season but improve
substantially during winter. Which clinical feature most strongly supports asthma?
A) Fixed symptoms without variation
B) Variable respiratory symptoms and airflow limitation over time
C) Progressive irreversible airflow limitation only
D) Persistent productive cough with no variability
Rationale: The correct answer is B. Asthma is characterized by variable respiratory symptoms
and variable expiratory airflow limitation. A fixed pattern is less characteristic. Progressive
persistent limitation may suggest COPD or another chronic lung disease.
Q5:
A patient with asthma has an Asthma Control Test score indicating poor control. Which
additional assessment is most important before modifying long-term therapy?
A) Hair color
B) Blood type
, 4|Page
C) Medication adherence and inhaler technique
D) Serum sodium alone
Rationale: The correct answer is C because poor adherence or incorrect inhaler technique can
mimic pharmacologic treatment failure. Correcting these factors may improve control without
unnecessarily escalating therapy.
Q6:
A patient has asthma symptoms primarily after exercise. Which statement best describes the
pathophysiological trigger?
A) Exercise permanently destroys alveolar walls
B) Exercise can provoke transient bronchoconstriction in susceptible patients
C) Exercise universally causes pulmonary fibrosis
D) Exercise directly causes bacterial pneumonia
Rationale: The correct answer is B. Exercise can trigger airway narrowing in susceptible
individuals through mechanisms involving airway cooling, drying, and mediator release. It does
not permanently destroy alveolar tissue or directly cause infection.
Q7:
A patient with asthma has frequent exacerbations despite reporting relatively few daily
symptoms. Which conclusion is most appropriate?
A) The patient has no meaningful asthma risk
B) Exacerbation risk should be assessed independently from current symptom frequency
C) Controller therapy should automatically be stopped
D) SABA use is irrelevant to future risk
Rationale: The correct answer is B. Asthma management considers both current symptom
control and future risk of exacerbations. A patient can have relatively few daily symptoms yet
remain at significant risk.
Q8:
A patient with asthma has poor control despite apparently appropriate prescribing. The patient
demonstrates incorrect inhaler technique during observation. What is the most appropriate
immediate intervention?
A) Add three additional controllers
B) Correct inhaler technique and reassess response before escalating therapy
C) Stop all inhaled medications
D) Begin lifelong oral corticosteroids
